Sildenafil (Viagra) Reduces Raynaud’s Frequency in Patients with Scleroderma
Modified-Release Therapy is Well Tolerated in Clinical Trial Researchers in Europe reported that treatment with modified-release sildenafil significantly reduced the frequency of attacks of Raynaud’s phenomenon in patients with limited cutaneous systemic sclerosis (lcSSc), also known as scleroderma. The double-blind, placebo-controlled trial found that sildenafil was well tolerated with only some subjects experiencing minor